ALS ONE Hosts Second Annual Massachusetts ALS Partnership Research Symposium
Annual Symposium Gathers Top Leaders, Researchers and Physicians to Accelerate Pathway to Finding Treatments for ALS
BOSTON, November 2, 2018 – Today, ALS ONE partnered with the ALS Association and ALS Finding a Cure to host the second annual Massachusetts ALS Partnership Research Symposium. Together, these partners are dedicated to unifying the top leaders, researchers, physicians, resources, expertise, and dedicated teams into a powerful coordinated team with single vision, and aligned goal of accelerating finding a treatment for ALS.
“In order to accelerate our progress in finding treatments for ALS, it’s critical that we continue to expand our collaboration model and share data and information with researchers from all over,” said Dr. Merit Cudkowicz, MD, Chief of Neurology, Massachusetts General Hospital (MGH) and ALS ONE partner. “We are proud to host our second annual Massachusetts ALS Research Symposium and are very excited to gather such an esteemed group of experts from around the country to convene with us here in Boston.”
This year’s symposium gathered more than 150 experts to explore and discuss the following themes, “Stress Granules and Nuclear – Cytoplasmic Transport” and “ALS Drug Development: New Concepts and Trial Design.” The event was funded by ALS ONE and was also sponsored by Biogen, Biohaven and Cytokinetics. Keynote speakers at the symposium, included: Clotilde Lagier-Tourenne, MD, PhDm Assistant in Neuroscience, Massachusetts General Hospital and Assistant Professor of Neurology, Harvard Medical School, as well as Chris Coffey, PhD, Director, Clinical Trials Statistical and Data Management Center (CTSDMC), Professor of Biostatistics, University of Iowa. Additional speakers at the event, included: Mark Sullivan, Chairman of the Board, ALS ONE; Lucie Bruijn, PhD, Chief Scientist ALS Association; Peter Foss, President, ALS Finding a Cure; Merit Cudkowicz, MD, MSc, Chief Medical Officer, MGH; Daryl Bosco, PhD, UMass Medical School. Claudia Fallini, PhD, UMass Medical School; Toby Ferguson, MD, PhD, Biogen; James Shorter, PhD, University of Pennsylvania; Jinsy Andrews, Columbia University; Steve Arnold, MD, MGH and Nazem Atassi, MD, MSc, MGH.
“We’re honored to help facilitate this important annual ALS Research Symposium,” said Mark Sullivan, Chairman of the Board of Directors for ALS ONE. “The discussions and collaboration fostered by today’s events will no doubt benefit the acceleration of ALS research worldwide.”
ALS ONE is a partnership of the top ALS experts from leading Massachusetts institutions, including Massachusetts General Hospital, UMass Medical School, ALS Therapy Development Institute, and Compassionate Care ALS. These venerable institutions are combining forces to expedite the path to find treatments or cure for ALS while improving care now. The approach of ALS ONE is to leverage the expertise of each of the research institutions through the share of ideas and responsibilities to advance each of the strongest therapeutic opportunities identified forward. Through the share of information, this partnership eliminates unnecessary duplication and is accelerating the path to finding ALS treatments. ALS ONE is also working to improve care for persons living with ALS by creating more access to clinical trials through education and transportation as well as providing technology, equipment, and support services to those battling the disease.
To learn more about ALS ONE, our partners and to donate to further the mission of care and cure for ALS, please visit www.ALSONE.org.
About ALS ONE
ALS ONE is a partnership of the top ALS experts from leading Massachusetts institutions, including UMass Medical School, Massachusetts General Hospital, ALS Therapy Development Institute, and Compassionate Care ALS. These venerable institutions are combining forces with the goal of finding a treatment or cure for ALS, while improving care now. The approach of ALS ONE is to leverage the expertise from each of the research institutions through the share of ideas and responsibilities to advance each of the strongest therapeutic opportunities identified forward. Through the share of information, this partnership will help eliminate unnecessary duplication and expedite the path to find ALS treatments. As the science and research efforts take time and significant funding, ALS ONE is also working to improve care for persons living with ALS by creating more access to clinical trials through education and transportation as well as providing technology, equipment and support services. ALS ONE is a non-profit 501c3. For more information, visit www.ALSONE.org.